Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of cediranib alone or with lomustine versus lomustine in recurrent glioblastoma
NL-OMON31263Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab and lomustine in glioblastoma (GBM) and brain neoplasm (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Nov 2007; status: not yet recruiting.
02
Drugs
bevacizumablomustine
03
Conditions
glioblastoma (GBM)brain neoplasm
Beyond the preview
Go deeper on NL-OMON31263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31263.